Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million, top end of prior guidance range.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst Pharmaceuticals (BCRX) Q3 Earnings Cheat Sheet
- BioCryst presents evidence on high adherence, persistence rates with ORLADEYO
- BioCryst to present real-world evidence on oral ORLADEYO
- Two Key Products Drive BioCryst (BCRX) to New Highs
- BioCryst reports inducement grants under Nasdaq listing rule